Xencor

Zenas zips up $118M to launch phase 3 for rare autoimmune disease candidate
Fierce Biotech
Tue, 11/8/22 - 10:22 pm
Zenas BioPharma
Xencor
funding
autoimmune disease
Xencor finally finds buyer for onetime lead drug, offloading autoimmune asset to Tesaro co-founder in backloaded deal
Fierce Biotech
Mon, 11/22/21 - 10:37 am
Xencor
obexelimab
Zenas BioPharma
autoimmune disease
Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further blow to hopes for blood cancer target
Fierce Biotech
Tue, 11/9/21 - 10:40 am
Novartis
Xencor
bispecifics
blood cancers
J&J spends $100M upfront, with $1.2B in biobucks, to join Roche and Regeneron in bispecific blood cancer race
Fierce Biotech
Mon, 10/4/21 - 11:08 am
JNJ
Xencor
biobucks
Roche
Regeneron
bispecific antibodies
blood cancers
plamotamab
J&J taps the bispecific experts at Xencor for prostate cancer discovery pact, kicking off with $50M upfront
Endpoints
Mon, 12/7/20 - 10:45 am
JNJ
Xencor
Janssen
bispecific antibodies
prostate cancer
Amgen tosses back unwanted bispecific to Xencor as KRAS data on track for 2020 readout
Fierce Biotech
Wed, 07/29/20 - 12:04 pm
Amgen
bispecific antibodies
Xencor
Armed with Nestlé cash, Aimmune grabs experimental food allergy drug form Xencor
Fierce Biotech
Wed, 02/5/20 - 09:58 am
Aimmune
Xencor
Nestle
AIMab7195
Palforzia
ASH2019 – Regeneron takes the bispecific baton and runs
EP Vantage
Wed, 12/11/19 - 10:21 am
ASH2019
Regeneron
Xencor
bispecific antibodies
REGN1979
lyphoma
Xencor begins phase 1 trial of XmAb23104 in advanced solid tumors
Pharmaceutical Business Review
Fri, 05/10/19 - 10:46 am
Xencor
solid tumors
bispecific antibodies
clinical trials
XmAb23104
Xencor, Astellas Pharma collaborate on novel bispecific antibody program
Pharmaceutical Business Review
Wed, 04/3/19 - 10:00 am
Xencor
Astellas
R&D
bispecific antibodies
Deaths spur partial hold for Xencor’s CD3 bispecific for leukemia, partnered with Novartis in $2.5B deal
Endpoints
Wed, 02/20/19 - 10:00 am
Xencor
XmAb14045
bispecific antibodies
acute myeloid leukemia
The bispecific boom: Genentech pays $120M to tie the knot with Xencor on an IL-15 alliance
Endpoints
Tue, 02/5/19 - 10:05 am
Genentech
Xencor
IL-15
XmAb24306
cancer
bispecific antibodies
In R&D rethink, Novartis ditches part of $2.6B Xencor bispecific pact
Fierce Biotech
Tue, 01/8/19 - 10:31 am
Novartis
Xencor
bispecific antibodies
This Caused Xencor Inc.'s Stock to Jump 11.6% in August
Motley Fool
Sun, 09/11/16 - 09:58 pm
Xencor
How Could the Novartis-Xencor Alliance Benefit Novartis?
Market Realist
Fri, 07/1/16 - 09:40 am
Novartis
Xencor
The Novartis-Xencor Collaboration Agreement: The Details
Market Realist
Fri, 07/1/16 - 09:37 am
Novartis
Xencor
monoclonal antibodies
Novartis jumps into bi-specific antibody space with $150 million Xencor deal
BioPharma Dive
Tue, 06/28/16 - 11:14 am
Novartis
bispecific antibodies
Xencor
acute myeloid leukemia
B-cell malignancies
Amgen, Xencor In $1.75 Billion Cancer Drug Alliance
Investors.com
Wed, 09/16/15 - 09:38 am
Amgen
Xencor
cancer
Xencor reports 4Q loss
Yahoo/AP
Fri, 02/20/15 - 10:19 am
Xencor
earnings
MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting
Yahoo/PR Newswire
Sun, 12/7/14 - 10:08 am
MorphoSys
Xencor
MOR208
chronic lymphocytic leukemia
leukemia

Pages